Figure 4.

Mutational Characterization of the PDX Panel

(A) Targeted sequencing for 360 cancer genes was performed on 47 PDXs, and WES was performed on an additional six PDXs. Copy number profiles were derived from these data. PDXs were grouped in pre-BRAF inhibitor treatment (pre-treatment), BRAF inhibitor-resistant (post-vemurafenib), intrinsic resistant, NRAS^Q61 mutant (NRAS), and BRAF^WTNRAS^WT PDXs and PDXs derived from five different lesions for a single patient after tumor-infiltrating lymphocytes therapy (post-TIL).

(B) Mutation matrix for 11 known melanoma driver genes. Total number of mutations per 1 Mb and the percentage of mutations with a C > T are indicated below the mutation matrix.